ADVENTRX Pharmaceuticals - Product Pipeline Review - Q4 2010

ADVENTRX Pharmaceuticals – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “ADVENTRX Pharmaceuticals - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ADVENTRX Pharmaceuticals - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ADVENTRX Pharmaceuticals human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ADVENTRX Pharmaceuticals with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ADVENTRX Pharmaceuticals’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ADVENTRX Pharmaceuticals’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ADVENTRX Pharmaceuticals in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ADVENTRX Pharmaceuticals’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ADVENTRX Pharmaceuticals.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ADVENTRX Pharmaceuticals and identify potential opportunities in those areas. SHOW LESS READ MORE >

List of Tables
List of Figures
ADVENTRX Pharmaceuticals Snapshot
ADVENTRX Pharmaceuticals Overview
Key Information
Key Facts
ADVENTRX Pharmaceuticals – Research and Development Overview
Key Therapeutic Areas
ADVENTRX Pharmaceuticals – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
ADVENTRX Pharmaceuticals – Pipeline Products Glance
ADVENTRX Pharmaceuticals – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
ADVENTRX Pharmaceuticals Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ADVENTRX Pharmaceuticals – Drug Profiles
Exelbine
Product Description
Mechanism of Action
R&D Progress
CoFactor
Product Description
Mechanism of Action
R&D Progress
CoFactor + 5-Fluorouracil
Product Description
Mechanism of Action
R&D Progress
CoFactor
Product Description
Mechanism of Action
R&D Progress
CoFactor + 5-Fluorouracil
Product Description
Mechanism of Action
R&D Progress
ANX-514
Product Description
Mechanism of Action
R&D Progress
ADVENTRX Pharmaceuticals – Pipeline Analysis
ADVENTRX Pharmaceuticals – Pipeline Products by Therapeutic Class
ADVENTRX Pharmaceuticals Pipeline Products By Target
ADVENTRX Pharmaceuticals – Pipeline Products by Route of Administration
ADVENTRX Pharmaceuticals – Pipeline Products by Molecule Type
ADVENTRX Pharmaceuticals – Recent Pipeline Updates
ADVENTRX Pharmaceuticals - Dormant Projects
ADVENTRX Pharmaceuticals - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ANX-015
ANX-016
ANX-513
ADVENTRX Pharmaceuticals – Company Statement
ADVENTRX Pharmaceuticals – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 03, 2010: ADVENTRX Submits Exelbine New Drug Application To FDA
Oct 06, 2010: ADVENTRX Receives Notice Of Allowance For Patent Claims For Exelbine
Oct 06, 2010: ADVENTRX Receives Notice Of Allowance For Patent Claims For Exelbine
Sep 14, 2010: ADVENTRX Announces 12-Month Stability Data Results For ANX-530
Jun 30, 2010: ADVENTRX Announces Nine-Month Stability Data Results For ANX-530
May 03, 2010: ADVENTRX Announces Stability Data Results For ANX-530
Mar 29, 2010: ADVENTRX Sets Meeting With FDA To Discuss ANX-530 NDA
Mar 29, 2010: ADVENTRX Sets Meeting With FDA To Discuss ANX-530 NDA
Mar 29, 2010: ADVENTRX Sets Meeting With FDA To Discuss ANX-530 NDA
Mar 29, 2010: ADVENTRX Sets Meeting With FDA To Discuss ANX-530 NDA
Financial Deals Landscape
ADVENTRX Pharmaceuticals, Deals Volume Summary, 2004 to YTD 2010
ADVENTRX Pharmaceuticals, Deals Summary By Region, 2004 to YTD 2010
ADVENTRX Pharmaceuticals, Deals Summary, 2004 to YTD 2010
ADVENTRX Pharmaceuticals Detailed Deal Summary
Acquisition
ADVENTRX Acquires SD Pharmaceuticals
Equity Offering
ADVENTRX Pharmaceuticals Completes Placement Of Series E Preferred Stock For $19 Million
ADVENTRX Completes Private Placement Of Series D Convertible Preferred Stock For $11 Million
ADVENTRX Pharmaceuticals Completes Private Placement Of $0.92 Million
ADVENTRX Pharmaceuticals Completes Public Offering Of $1.36 Million
ADVENTRX Pharmaceuticals Completes Private Placement Of $2 Million
ADVENTRX Completes Private Placement Of $8 Million
ADVENTRX Completes Public Offering Of $40 Million
ADVENTRX Completes Private Placement Of $3 Million
ADVENTRX Completes Private Placement Of $20 Million
ADVENTRX Completes Private Placement Of $15 Million
ADVENTRX Pharmaceuticals Withdraws Public Offering Of Common Stock
Licensing Agreements
SD Pharmaceuticals Enters Into Licensing Agreement With Shin Poong
SD Pharmaceuticals Enters Into Licensing Agreement With Theragenex
ADVENTRX Enters Into License Agreement With SD Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer